HeartBeam (BEAT) Q2 FY26 earnings call

HeartBeam is rapidly advancing its heart attack detection program, submitting its pre-submission to the FDA and seeing strong clinical trial enrollment. The initial commercial launch in the concierge market is gaining traction with workflow integration, and the company has significantly reduced its operating cash burn, extending its financial runway. Management remains focused on core priorities and expects accelerated revenue growth in the second half of the year.